APA (7th ed.) Citation

Charbonnel, B., Dormandy, J., Erdmann, E., Masssi-Benedetti, M., Skene, A., Massi-Benedetti, M., & Group, P. S. (2004). The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care, 27(7), 1647. https://doi.org/10.2337/diacare.27.7.1647

Chicago Style (17th ed.) Citation

Charbonnel, Bernard, John Dormandy, Erland Erdmann, Massimo Masssi-Benedetti, Allan Skene, Massimo Massi-Benedetti, and PROactive Study Group. "The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can Pioglitazone Reduce Cardiovascular Events in Diabetes? Study Design and Baseline Characteristics of 5238 Patients." Diabetes Care 27, no. 7 (2004): 1647. https://doi.org/10.2337/diacare.27.7.1647.

MLA (9th ed.) Citation

Charbonnel, Bernard, et al. "The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can Pioglitazone Reduce Cardiovascular Events in Diabetes? Study Design and Baseline Characteristics of 5238 Patients." Diabetes Care, vol. 27, no. 7, 2004, p. 1647, https://doi.org/10.2337/diacare.27.7.1647.